A Recurrent Giant Cell Tumor of Bone Treated with Denosumab
Department of Orthopaedics, Klinikum Wels-Grieskirchen, Wels, Austria
*
Author to whom correspondence should be addressed.
Clin. Pract. 2015, 5(1), 697; https://doi.org/10.4081/cp.2015.697
Submission received: 6 August 2014
/
Revised: 23 October 2014
/
Accepted: 12 November 2014
/
Published: 10 February 2015
Abstract
Although the giant cell tumor of bone is generally classified as a benign tumor it can rarely metastasize and has a potential risk of local recurrence. We want to report about a female patient who suffered from a recurrence of a giant cell tumor of bone after the implantation of a total endoprosthesis of the knee joint. We have treated her with denosumab, which is a receptor activator of nuclear factor kappa-B ligand inhibitor. In this case report we want to present a new option to treat this kind of neoplasm.
Share and Cite
MDPI and ACS Style
Stadler, N.; Fingernagel, T.; Hofstaetter, S.G.; Trieb, K. A Recurrent Giant Cell Tumor of Bone Treated with Denosumab. Clin. Pract. 2015, 5, 697. https://doi.org/10.4081/cp.2015.697
AMA Style
Stadler N, Fingernagel T, Hofstaetter SG, Trieb K. A Recurrent Giant Cell Tumor of Bone Treated with Denosumab. Clinics and Practice. 2015; 5(1):697. https://doi.org/10.4081/cp.2015.697
Chicago/Turabian StyleStadler, Nicola, Thomas Fingernagel, Stefan G. Hofstaetter, and Klemens Trieb. 2015. "A Recurrent Giant Cell Tumor of Bone Treated with Denosumab" Clinics and Practice 5, no. 1: 697. https://doi.org/10.4081/cp.2015.697
